·················································································································································································································································································································································································································································································
早在上世纪60年代，α硫辛酸已被列入西方的药典；到90年代初，西方市场也开发上市了多种α硫辛酸类保健产品。而α硫辛酸真正引起世人瞩目是在切尔诺贝利核电站爆炸事故发生后，当时苏联卫生部紧急向切尔诺贝利附近居民大量分发α硫辛酸口服剂作为抗辐射预防药物并取得良好效果。从此，α硫辛酸的抗辐射作用才被认识和重视
亚宝药业(600351)公告，公司获得国家药监局核准签发的硫辛酸片两个规格的药品注册证书。
